{View as Webpage}

October 2026

Featured Publication


Nikhit Kethidi, MD; Saurabh Mehandru, MD; Samir Parekh, MBBS, and colleagues


Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy

Nature Medicine. 2026 Sep 23. PMID: 42778764


This study identifies biological mechanisms that may contribute to CAR-T cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR-T cell therapy for multiple myeloma. It showed that CAR-T cells can persist in the intestinal tissue long after treatment and that patients who develop enterocolitis experience widespread changes in the immune system within the gut. The research provides the first detailed map of what happens in the intestine in patients who develop CAR-T-associated enterocolitis and identifies biological pathways that may be targeted therapeutically.

 

Press Release

RAS Symposium

Keynote Speaker: Frank McCormick, PhD, FRS

UCSF Helen Diller Family Comprehensive Cancer Center


Program****Flyer****Event Information

Please contact Swagata Basu if you would like to register.

TCC Seminar Series


Mount Sinai Tisch Cancer Center

Seminar Series


Tuesdays at noon, Davis Auditorium


October 13

Andy Minn, MD, PhD

Chair, Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center

“Chronic Inflammation and Mechanisms of Cancer Immunotherapy Resistance”

Hosted by Emily Bernstein, PhD

 

October 20

Yu Chen, MD, PhD

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

“Transcription Dysfunction in Tumor Initiation and Progression”

Hosted by Juan Arriaga, PhD

 

October 27

Zachary Hartman, PhD

Associate Professor of Surgery, Pathology, and Integrative Immunobiology

Duke University School of Medicine

"Harnessing Therapy-Induced Immunity With ADCs and Cancer Vaccines"

Hosted by Javier Bravo-Cordero, PhD


See complete schedule, September - December

Faculty Efforts Lead to FDA Approval

The U.S. Food and Drug Administration recently approved MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Approval was in large part due to results of the phase 2 study, for which Mount Sinai was the lead site. Marina Kremyanskaya, MD, PhD; Ronald Hoffman, MD; Yelena Ginzburg, MD, and research team led the effort and were instrumental in development of the phase 3 study. Results of the phase 2 study were reported in The New England Journal of Medicine. 

Grant Awards

Maaike van Gerwen, PhD, has been awarded R21 funding from the National Institute for Occupational Safety and Health for “Mechanisms of WTC Dust-Induced Thyroid Cancer Progression in Organoids.” Exposure to endocrine-disruption chemicals present in World Trade Center (WTC) dust may contribute to the elevated incidence of thyroid cancer in WTC-exposed populations. Using novel thyroid (cancer) organoid models in toxicology research of WTC dust in combination with cutting-edge multiomics techniques, this project aims to understand the pathways of WTC-related thyroid cancer. Findings may inform future strategies for risk assessment, early detection, clinical surveillance, and preventive measures following exposure.

Ya-Wen Chen, PhD, and Eric Genden, MD, are co-investigators.

Eirini Papapetrou, MD, PhD, has been awarded R01 funding from the National Cancer Institute for “Targeting Inflammatory RAS-Mutated AML Leukemia Stem Cells.” RAS pathway mutations have recently emerged as a major driver of resistance in acute myeloid leukemia in the era of newer targeted therapies, including the BCL2, FLT3 and IDH1/2 inhibitors. This proposal builds upon recent work in the Papapetrou Lab on unique properties of RAS-mutant leukemia stem cells, to identify and test new therapeutic targets, specific to RAS-mutant acute myeloid leukemia stem cells. Marina Konopleva, MD, PhD, with Montefiore Einstein is Co-PI.

Stephanie Blank, MD, Chung Yin (Joey) Kong, PhD, and colleagues have been awarded renewed U01 funding from the National Cancer Institute for “Comparative Modeling for the Prevention and Control of Uterine Cancer.” The overarching goal of this project is to inform cancer control and prevention strategies to reduce uterine cancer incidence and mortality by improving the prevention, screening, and treatment of the disease. A collaborative modeling consortium involving Mount Sinai, Columbia, Duke, and Tufts is focused on developing natural history models of uterine cancer that incorporate known risk factors and population level changes in the prevalence of these risk factors over time.

Susanna Curtis, MD, PhD, was awarded R01 funding from the National Heart Lung and Blood Institute for “Inflammatory Biosignatures for the Identification of Sickle Cell Associated Pain Phenotypes (IBIS-CAP).” Dr. Curtis will develop proteomic signatures to identify phenotypes of chronic pain in sickle cell disease. She will examine these signatures using longitudinal data and genomic data to perform a network analysis to determine drivers of chronic pain phenotypes. This will be done in the context of a randomized study of dronabinol, a safe low-cost FDA approved agent, which will serve as proof of concept that agents that target pathways involved in signatures of a pain phenotype will have superior outcomes on that phenotype.

The services of the Mount Sinai Tisch Cancer Center Biostatistics Shared Resource can significantly increase the likelihood of successful grant awards. The first step in the process is to submit a request for services.

 

Questions? Contact Erin Moshier, MSc, Managing Director.

Publications

Nicole Tignor, PhD; Pei Wang, PhD, and colleagues

 

Proteogenomic analysis of pediatric and AYA high-grade glioma reveals age-dependent biology, female-male differences, and kinase targets

Cell Reports Medicine. 2026 Sep 17. PMID: 42753723

 

Multi-omics analysis of tumors from pediatric and young adult patients with high-grade gliomas identified age- and sex-dependent biology, candidate kinase targets, and proteins and immune signatures associated with poor survival outcomes. Findings can be used to inform clinical trial design and develop new therapies that advance more precise treatment strategies. The study was conducted by the Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute, the Children’s Brain Tumor Network, and the Philadelphia Coalition for a Cure. 

 

Press Release

Chiara Falcomata, PhD; Brian Brown, PhD, and colleagues

 

A serpin-myeloid axis in pancreatic cancer heterogeneity and immune evasion

Nature. 2026 Sep 9. PMID: 42717081

 

Using Perturb-map spatial functional genomics, Dr. Brown and team determined how different genes shape the growth and cellular environments of pancreatic ductal carcinoma (PDAC) clones across space and time. The analysis revealed early gene-driven remodeling of local immune neighborhoods preceding late-stage spatial clonal dominance. The findings identify cancer-derived SERPINE1 and SERPINB2 as local spatial organizers of immune suppression, linking tumor-intrinsic heterogeneity to local microenvironmental control and immunotherapy resistance in PDAC, and inform a potential strategy for overcoming pancreatic cancer's resistance to immune-based treatments. 

 

Press Release

Jian Jin, PhD, and colleagues



PRMT7 restricts CD8+ T cells expansion via the NF-κB pathway

Nature Communications. 2026 Sep 6.

 

Jian Jin, PhD, and Stéphane Richard, PhD, (McGill University) led a research team that developed the first-in-class PRMT7 degrader, MS54. PRMT7, a protein arginine methyltransferase, acts as a checkpoint on CD8+ T cell proliferation through a non-enzymatic protein–protein interaction with RelA (p65), a core subunit of the NF-κB pathway, restricting its translocation into the nucleus. Pharmacological degradation of PRMT7 by MS54 releases this constraint, driving NF-κB activation and upregulating key T cell activation markers. MS54 successfully boosted CD8+ T cell proliferation and antitumor activity in preclinical melanoma models.

Sacha Gnjatic, PhD, and colleagues



Safety and biomarker analysis of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1 high locally advanced non-small cell lung cancer

International Journal of Radiation Oncology, Biology, Physics. 2026 Sep 12. PMID: 42731785

 

This trial tested whether it was safe to give standard or accelerated radiotherapy (RT) combined with the anti-PD-L1 drug durvalumab in patients with locally advanced lung cancer expressing high PD-L1 levels as an alternative to chemotherapy and RT followed by PD-1 blockade. Findings showed that chemotherapy-free thoracic RT with either standard fractionated or accelerated courses with concurrent durvalumab is safe and well tolerated in this patient population. Further, immune monitoring, funded by a U24 CIMAC grant from the National Cancer Institute for exploratory biomarkers, indicated greater immune changes with standard RT versus accelerated RT and shed light on possible predictors of adverse events.

Douglas Tremblay, MD; Dahniel Sastow, MD; John Mascarenhas, MD; Ronald Hoffman, MD, and colleagues



Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis

Blood Advances. 2026 Aug 20. PMID: 42623680

 

In the largest cohort of MPN-associated splanchnic vein thrombosis (SVT) patients studied to date, Douglas Tremblay and team analyzed 757 patients from the international GASTRO-MPN Consortium, treating cytoreductive therapy as a time-dependent covariate to account for starts, stops, and switches in treatment. Over a median follow-up of 7.4 years, cytoreductive therapy was associated with a 33% reduction in recurrent thrombosis risk, driven primarily by lower rates of SVT extension/recurrence, with no significant impact on bleeding risk. These findings provide the strongest evidence to date supporting cytoreductive therapy's role in preventing recurrent thrombosis in this population.

Franco Izzo, PhD; Tamara Prieto, PhD, and colleagues

 

A single-cell lens into the co-evolution of genotypes and phenotypes in cancer

Nature Reviews Cancer. 2026 Sep 8. PMID: 42711452

 

This review discusses multimodal single-cell technologies that enable the measurement of genotypes and additional molecular features from the same cell—these technologies unveil mutant-specific phenotypic traits and can define therapeutic vulnerabilities for precision elimination of disease-propagating mutant cells. Genotype–phenotype and temporal mapping of somatic evolution in human tissues offers a new framework for understanding the biology of cancer development across stages, from pre-cancer states to cancer onset, progression and therapy resistance.

Edmund Charles Jenkins, PhD; Doris Germain, PhD, and colleagues

 

Mitochondria dictate progressive versus bimodal aging of the mammary gland

Aging Cell. 2026 Aug 25. PMID: 42572130

 

Breast cancer shows a bimodal age distribution with a peak at 45 and higher peak at 65. Using mice with different mitochondrial genomes, Dr. Germain and team show progressive and bimodal patterns of aging of the mammary gland with distinct pro‐tumorigenic age windows. This finding may shed light on the bimodal distribution in humans. The study also adds to the growing evidence of non‐linear aging.

Keith Sigel, MD, PhD, and colleagues

 

Impact of beta blockers, statins, and cholinergic agents on clinical outcomes in pancreatic cancer: a retrospective VA cohort study

Cancer Epidemiology, Biomarkers & Prevention. 2026 Aug 18. PMID: 42611506

 

This retrospective study of 7,578 Veterans with pancreatic cancer showed that exposure to commonly prescribed medications, in particular beta blockers, was associated with notable differences in stage at diagnosis and survival outcomes. Findings suggest that pharmacologic modulation of sympathetic and parasympathetic signaling, as well as cholesterol metabolism, may influence tumor biology and clinical outcomes in pancreatic cancer, with beta blockers showing the most consistent association with benefit.

Upcoming Events

Wednesday, October 14

9 am – 5:30 pm

NYU Langone


More Information

50th International Conference on Screening for Lung Cancer (I-ELCAP) and

18th Initiative for Early Lung Cancer Research and Treatment Conference (IELCART)

 

October 22-24

Goldwurm Auditorium

No fee, in-person and virtual

Registration

Chemotherapy Foundation Symposium

November 11-13, New York Hilton Downtown


John Mascarenhas, MD, Co-Chair

Use Code MASCARENHAS for free registration

Friday, November 20

8:30 am - 4:30 pm

Davis Auditorium


More Information

Advances in the Pathogenesis and Immune Therapies of Liver Cancer

December 6-8

Hyatt Regency Austin

Josep Llovet, MD, PhD, Co-Chair

Abstract submission deadline: September 23

Conference Flyer 

Presentations

 

 

  • Tristen Park, MD, was senior author on a presentation by former breast surgical oncology fellow, Andrew Seto, MD, now at Boston Medical Center, at the Taipei International Breast Cancer Symposium, held September 19-20. The presentation, “Clinicopathologic Characteristics of Asian American Breast Cancer Patients: A Twelve-Year Single-Institution Experience,” highlighted research conducted at Mount Sinai.

Community Outreach

Alexandra Gori, MPH, with the Community Outreach and Engagement (COE) program, presented "From Pantry to Prevention: Building Trusting New York City Partnerships to Advance Equitable Cancer Screening" at the annual Cancer Center Community Impact Forum conference in Seattle, held September 27-29. The poster highlighted how COE is building trusting partnerships to advance cancer control in TCC’s catchment area communities.

CANCER IN THE NEWS - CLICK HERE



 

Do you have news for the next issue of TCC Connections? 


Please send to Janet.Aronson@mountsinai.org.


Remember to share breaking news and high impact news that might be appropriate for media coverage with Diego Ortiz Quintero in the Press Office. This may include pending FDA drug/device approvals, studies/trial results being published in high-impact journals, and patient stories. The more lead time you can give Diego, the better—ideally, four weeks or when a paper is accepted by the journal. Embargoes will always be honored and news will only be released with your approval. Contact Diego at diego.ortizquintero@mountsinai.org or 201-572-5703.

 
 
Twitter  

  TCC Connections  is a monthly publication of the Mount Sinai Tisch Cancer Center

Ramon Parsons, MD, PhD, Director

Janet Aronson , Editor

Past issues of  TCC Connections  are available on the Mount Sinai Tisch Cancer Center website